Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...
Analysts expressed concerns about R&D spending, vaccine sales uncertainties ... s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.
P.E.I.'s chief public health officer is working towards expanding eligibility for RSV vaccines as the province experiences high levels of respiratory illnesses this season. Dr. Heather Morrison ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines ... and Daiichii Sankyo’s antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback